Dr. Negrin University Hospital - Recruiting 18 years to 75 years. - Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation.
18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.
Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide
Roswell Park Cancer Institute - Recruiting 18 years or older. - Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas.
Amgen - Recruiting 18 years or older. - A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
Beth Israel Medical Center - Recruiting 18 years to 70 years. - STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
to-BBB technologies B.V. - Recruiting 18 years or older. - An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks
Duke University - Recruiting 18 years or older. - A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure.
Lipopharma Therapeutics SL - Recruiting 18 years or older. - A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minervalr) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma.
Kentuckiana Cancer Institute - Recruiting 18 years to 75 years. - A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma.